April 22nd 2024
Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
The Future of Neoadjuvant Immunotherapy in MIBC
December 20th 2022Dr Terence Friedlander closes his discussion by highlighting ongoing clinicals in neoadjuvant MIBC treatment that excite him and speculates on how he would use immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant setting.
Watch
FDA Accepts sBLAs for Enfortumab Vedotin and Pembrolizumab in Locally Advanced or Metastatic UC
December 20th 2022For patients with locally advanced or metastatic urothelial cancer, the FDA has accepted for priority review supplemental biologics license applications for enfortumab vedotin-ejfv and pembrolizumab.
Read More
Genentech Withdraws Atezolizumab Indication for Certain Patients with Metastatic Bladder Cancer
November 29th 2022New phase 3 data has led to Genentech removing the US indication of atezolizumab for treatment of patients ineligible for cisplatin chemotherapy with metastatic urothelial carcinoma.
Read More
Roundtable Discussion: Looking at the Role of Avelumab Maintenance in Metastatic Bladder Cancer
November 29th 2022During a Targeted Oncology case-based roundtable event, Daniel Petrylak, MD, discussed with participants the case of a patient with bladder cancer who has lung metastases and significant pulmonary comorbidities.
Read More
Roundtable Discussion: Barata and Participants Explore Later-Line Options in Bladder Cancer
November 22nd 2022During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed with participants their approaches to therapy for a patient whose bladder cancer progresses after receiving chemotherapy and immunotherapy.
Read More
AVENANCE: Early Activity Shown With Avelumab in Metastatic Urothelial Carcinoma
October 26th 2022In an interview with Targeted Oncology, Philippe Barthelemy, MD, discussed the preliminary findings of the AVENANCE trial of avelumab in patients with advanced or metastatic urothelial carcinoma.
Read More
Clinical Benefit and Safety of Avelumab/BSC Upheld With Long-Term Data From JAVELIN Bladder 100
October 14th 2022In an interview with Targeted Oncology, Jeanny B. Aragon-Ching, discussed recent updates from the JAVELIN Bladder 100 trial. She also discussed ongoing research involving the novel agent EV-103 in patients with advanced or metastatic urothelial cancer.
Read More
Enfortumab Vedotin/Pembrolizumab Elicits High Response Rates in Urothelial Cancer
September 19th 2022In an interview with Targeted Oncology, Jonathan Rosenberg, MD, further discussed the background and results of the EV-103 study in patients with locally advanced metastatic urothelial cancer.
Read More
Biomarkers May Help Predict Responses to Avelumab in Urothelial Carcinoma
September 11th 2022Multiple blood-based biomarkers suggest potential responses to treatment with maintenance avelumab for patients with advanced or metastatic urothelial carcinoma from the phase 3 JAVELIN Bladder 100 trial, according to an exploratory analysis presented at the European Society for Medical Oncology Congress 2022.
Read More
Doctors Debate: Should Systemic Therapy for UTUC Be Given in the Adjuvant or Neoadjuvant Setting?
August 25th 2022During the 2022 Debates and Didactics in Hematology and Oncology conference, Bassel Nazha, MD, MPH and Jacqueline T. Brown, MD, debated on adjuvant vs neoadjuvant systemic therapy for patients with upper tract urothelial cancer.
Read More